The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to treatment after surgery might help those who still have traces of cancer in their blood. The analysis showed that patients with signs of cancer in their blood measured by Signatera™, a circulating tumor DNA (ctDNA) test, tended to have worse outcomes. However, those who took celecoxib after surgery had a much better chance of staying cancer-free. These results are being presented in a late-breaking abstract and highlighted in the press program during the 2025 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium, in San Francisco, CA.

 Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission. The team identified that a key cell type in the DLI product and features of the tumor microenvironment in patients both play a role.

A study presented this week at The Society of Thoracic Surgeons’ 61st Annual Meeting explores findings in more than a million U.S. Medicare beneficiaries who underwent CABG from 2001 to 2019. The researchers found that patients who received multi-arterial grafting (MAG) had improved survival over those who received single-arterial grafting (SAG), supporting findings from prior retrospective studies.

Researchers find blocking the KCNB2 gene can slow tumour growth, paving the way for next-gen treatments for childhood brain cancer.